Richard Stratton

3.3k total citations
80 papers, 2.3k citations indexed

About

Richard Stratton is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Dermatology. According to data from OpenAlex, Richard Stratton has authored 80 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pathology and Forensic Medicine, 28 papers in Molecular Biology and 23 papers in Dermatology. Recurrent topics in Richard Stratton's work include Systemic Sclerosis and Related Diseases (42 papers), Dermatologic Treatments and Research (17 papers) and Connective Tissue Growth Factor Research (16 papers). Richard Stratton is often cited by papers focused on Systemic Sclerosis and Related Diseases (42 papers), Dermatologic Treatments and Research (17 papers) and Connective Tissue Growth Factor Research (16 papers). Richard Stratton collaborates with scholars based in United Kingdom, United States and Canada. Richard Stratton's co-authors include David Abraham, Shiwen Xu, Andrew Leask, Christopher P. Denton, C. M. Black, Carol M. Black, Joanna Nikitorowicz-Buniak, C.C. Bunn, Edward Kingdon and Henry Penn and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Richard Stratton

67 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Stratton United Kingdom 26 1.1k 792 508 496 405 80 2.3k
Vivien Hsu United States 22 1.4k 1.3× 280 0.4× 522 1.0× 471 0.9× 650 1.6× 43 2.1k
Joseph H. Korn United States 36 1.5k 1.4× 951 1.2× 737 1.5× 654 1.3× 696 1.7× 71 3.5k
Monique Hinchcliff United States 36 1.9k 1.7× 840 1.1× 591 1.2× 615 1.2× 953 2.4× 97 3.5k
Nicolas Hunzelmann Germany 32 1.8k 1.6× 362 0.5× 738 1.5× 731 1.5× 243 0.6× 140 3.2k
Paola Sambo Italy 15 704 0.6× 364 0.5× 279 0.5× 494 1.0× 202 0.5× 26 1.5k
Stéphane Barète France 30 454 0.4× 244 0.3× 463 0.9× 777 1.6× 274 0.7× 117 2.3k
Simone Negrini Italy 29 582 0.5× 612 0.8× 225 0.4× 1.3k 2.6× 334 0.8× 88 3.6k
Stefano Bombardieri Italy 30 804 0.7× 346 0.4× 264 0.5× 438 0.9× 290 0.7× 88 3.3k
Itzhak Rosner Israel 31 428 0.4× 492 0.6× 150 0.3× 620 1.3× 293 0.7× 135 2.7k

Countries citing papers authored by Richard Stratton

Since Specialization
Citations

This map shows the geographic impact of Richard Stratton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Stratton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Stratton more than expected).

Fields of papers citing papers by Richard Stratton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Stratton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Stratton. The network helps show where Richard Stratton may publish in the future.

Co-authorship network of co-authors of Richard Stratton

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Stratton. A scholar is included among the top collaborators of Richard Stratton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Stratton. Richard Stratton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stratton, Richard, et al.. (2024). Digital ulcers associated with scleroderma: A major unmet medical need. Wound Repair and Regeneration. 32(6). 949–959.
2.
Beynon, Huw, et al.. (2024). Chilblain lupus induced by infliximab therapy. Rheumatology Advances in Practice. 9(2). rkaf027–rkaf027.
3.
Leask, Andrew, et al.. (2023). Back to the future: targeting the extracellular matrix to treat systemic sclerosis. Nature Reviews Rheumatology. 19(11). 713–723. 28 indexed citations
4.
Brown, James, Richard Stratton, Roberto Buccafusca, et al.. (2023). Identification of autoantigens and their potential post-translational modification in EGPA and severe eosinophilic asthma. Frontiers in Immunology. 14. 1164941–1164941. 1 indexed citations
5.
Xu, Shiwen, John Nguyen, David E. Carter, et al.. (2023). Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Annals of the Rheumatic Diseases. 82(9). 1191–1204. 15 indexed citations
6.
Xu, Shiwen, et al.. (2021). Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. Journal of Cell Communication and Signaling. 15(1). 71–80. 29 indexed citations
7.
Henderson, John, et al.. (2020). Wnt antagonist DKK‐1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a‐3p. Experimental Dermatology. 30(1). 162–168. 19 indexed citations
8.
Henderson, John, et al.. (2020). Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis. Journal of Cellular and Molecular Medicine. 24(23). 14026–14038. 54 indexed citations
9.
Denton, Christopher P., et al.. (2020). Iloprost for COVID-19-related vasculopathy. The Lancet Rheumatology. 2(10). e582–e583. 13 indexed citations
10.
Tansley, Sarah, Zoë Betteridge, Hui Lu, et al.. (2019). The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. Lara D. Veeken. 59(7). 1626–1631. 15 indexed citations
11.
Xu, Shiwen, Yizhi Xiao, Shangxi Liu, et al.. (2019). CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis. SHILAP Revista de lepidopterología. 3. 100009–100009. 17 indexed citations
12.
Xu, Shiwen, et al.. (2017). Antioxidants and NOX1/NOX4 inhibition blocks TGFβ1-induced CCN2 and α-SMA expression in dermal and gingival fibroblasts. PLoS ONE. 12(10). e0186740–e0186740. 31 indexed citations
13.
Strange, Adam, Sebastián Aguayo, Nicola Mordan, et al.. (2017). Quantitative nanohistological investigation of scleroderma: an atomic force microscopy-based approach to disease characterization. International Journal of Nanomedicine. Volume 12. 411–420. 14 indexed citations
14.
Stratton, Richard, et al.. (2015). Don’t stop till you get enough: Factors driving men towards muscularity. Body Image. 15. 72–80. 41 indexed citations
15.
Nikitorowicz-Buniak, Joanna, Shiwen Xu, Andrew Leask, et al.. (2011). Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. PubMed. 4(1). 13–13. 18 indexed citations
16.
Stratton, Richard, et al.. (2008). Autoimmunity and HIV. Current Opinion in Infectious Diseases. 22(1). 49–56. 34 indexed citations
17.
Xu, Shiwen, Laura Kennedy, Daphne Pala, et al.. (2006). CCN2 Is Necessary for Adhesive Responses to Transforming Growth Factor-β1 in Embryonic Fibroblasts. Journal of Biological Chemistry. 281(16). 10715–10726. 136 indexed citations
18.
Stratton, Richard, Shiwen Xu, Giorgia Martini, et al.. (2001). Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. Journal of Clinical Investigation. 108(2). 241–250. 26 indexed citations
19.
Stratton, Richard, et al.. (2000). Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Annals of the Rheumatic Diseases. 59(2). 132–134. 19 indexed citations
20.
Yamamoto, Takashi, et al.. (1988). Nucleotide sequence of the gene coding for a 130-kDa mosquitocidal protein of Bacillus thuringiensis israelensis. Gene. 66(1). 107–120. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vivien Hsu Breakdown of academic impact, for papers by Joseph H. Korn Breakdown of academic impact, for papers by Monique Hinchcliff Breakdown of academic impact, for papers by Nicolas Hunzelmann Breakdown of academic impact, for papers by Paola Sambo Breakdown of academic impact, for papers by Stéphane Barète Breakdown of academic impact, for papers by Simone Negrini Breakdown of academic impact, for papers by Stefano Bombardieri Breakdown of academic impact, for papers by Itzhak Rosner
Rankless by CCL
2026